MAPT and frontotemporal dementia: No alterations of the synaptic and total levels of NMDAR subunits were observed in anti-GluA3-positive FTD-tau patients, thus suggesting that GluA3 antibodies target AMPAR without interfering with other glutamate receptor subtypes [1].